Skip to main content

COVID-19 Vaccines

Infectious Diseases
3
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Infectious Diseases is an $11.9B market dominated by HIV and hepatitis C treatments in their peak revenue phases, reflecting a mature but stable therapeutic area.

$11.9B marketMature→ Stable30 products15 companies

Key Trends

  • HIV antiretroviral dominance: Nucleoside Reverse Transcriptase Inhibitors account for 44% of spending
  • Patent cliff pressure: $2.8B in revenue from major products facing LOE between 2027–2031
  • High trial velocity: 9,337 active trials indicate sustained pipeline development despite market maturity

Career Verdict

Infectious Diseases offers stable, well-compensated roles with strong commercial demand, but limited growth upside—ideal for risk-averse professionals seeking established franchises rather than high-growth opportunities.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1BIKTARVYStable
$3.2B
Gilead Sciences·Peak10.5yr
#2EPCLUSAStable
$877M
Gilead Sciences·Peak8.1yr
#3TIVICAYDeclining
$657M
GSK·Peak4.1yr
#4TRIUMEQDeclining
$632M
GSK·Peak4.1yr
#5GENVOYAStable
$626M
Gilead Sciences·Peak6.9yr

Drug Class Breakdown

Nucleoside Reverse Transcriptase Inhibitors
$5.2B(44%)

backbone of HIV treatment, stable demand

RNA Replicase Inhibitors
$1.8B(15%)

hepatitis C treatment, mature market

Cytochrome P450 3A Inhibitors
$1.4B(12%)

boosting agents in combination regimens

P-Glycoprotein Inhibitors
$343M(3%)

niche mechanism, limited growth

Career Outlook

Stable

Infectious Diseases offers predictable career progression and above-average compensation in Commercial roles, supported by 780 current openings and sustained demand from market incumbents. However, patent cliffs affecting $2.8B in near-term revenue (2027–2031) will compress margins and slow hiring after 2028, particularly in Commercial support and field-based roles. The area is best suited for mid-career professionals seeking stability over rapid growth, with limited appeal for early-career scientists pursuing innovation-driven research.

Breaking In

Enter via Commercial or Manufacturing roles at GSK, Sanofi, or Becton Dickinson to build market expertise and commanding salaries ($160K–$237K); avoid pure R&D tracks unless you target specific mechanisms like long-acting injectables.

For Experienced Professionals

Experienced professionals should pursue Market Access, Medical Affairs, or Commercial Leadership roles where patent cliff expertise commands premium compensation; consider consulting or biotech transition if R&D innovation is your priority.

In-Demand Skills

Market access and payer strategyBrand management in generic-transition environmentsManufacturing scale-up and supply chain optimizationMedical science liaison (MSL) capabilities for physician engagementHealth economics and real-world outcomes analysis

Best For

Brand ManagerMarket Access ManagerMedical Science LiaisonSales DirectorManufacturing EngineerHealth Economics Analyst

Hiring Landscape

$160K–$275K

Infectious Diseases hiring is heavily weighted toward Commercial roles (247 positions, 32% of total), reflecting mature market dynamics focused on market access and brand management. GSK and Becton Dickinson lead hiring (214 and 188 roles), but Gilead Sciences—the market leader by revenue—shows surprisingly low hiring (25 roles), signaling efficiency-driven operations. Salary progression favors Commercial ($275K avg) over R&D ($184K avg), indicating career acceleration through sales and marketing functions.

780
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

214Growing
100Stable
61Stable
51Growing

By Department

Commercial(32%)
$275K
Engineering(16%)
$237K
Manufacturing(14%)
$160K
Research & Development(9%)
$184K

Strong Commercial hiring with premium salaries suggests Infectious Diseases is an excellent landing spot for brand, sales, and market access professionals, but limited R&D hiring indicates reduced innovation investment.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Syneos Health
Syneos HealthNC - Morrisville
1 program
1
UB-612Phase 31 trial
Active Trials
NCT05293665Unknown944Est. Sep 2023
Vaxxinity
VaxxinityTX - Dallas
1 program
1
UB-612Phase 3
Eppendorf
EppendorfGermany - Hamburg
1 program
1
MVA-SARS-2-STPhase 11 trial
Active Trials
NCT05226390Terminated23Est. Nov 2023
Biocorp
BiocorpFrance - Issoire
1 program
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control StudyN/A1 trial
Active Trials
NCT05621928Unknown3,920Est. Dec 2024
Nia Therapeutics
Nia TherapeuticsMA - Boston
1 program
High touch multi-pronged behavioral interventionN/A1 trial
Active Trials
NCT04732819Completed23,768Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Syneos HealthUB-612
EppendorfMVA-SARS-2-ST
BiocorpEffectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
Nia TherapeuticsHigh touch multi-pronged behavioral intervention

Clinical Trials (4)

Total enrollment: 28,655 patients across 4 trials

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Start: Mar 2022Est. completion: Sep 2023944 patients
Phase 3Unknown

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

Start: Feb 2022Est. completion: Nov 202323 patients
Phase 1Terminated
NCT05621928BiocorpEffectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study

Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study

Start: Feb 2022Est. completion: Dec 20243,920 patients
N/AUnknown
NCT04732819Nia TherapeuticsHigh touch multi-pronged behavioral intervention

Improving COVID-19 Vaccine Uptake in Nursing Homes

Start: Dec 2020Est. completion: Apr 202123,768 patients
N/ACompleted

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.